These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 20384344)

  • 21. Development of chiral N-alkylcarbamates as new leads for potent and selective H3-receptor antagonists: synthesis, capillary electrophoresis, and in vitro and oral in vivo activity.
    Sasse A; Kiec-Kononowicz K; Stark H; Motyl M; Reidemeister S; Ganellin CR; Ligneau X; Schwartz JC; Schunack W
    J Med Chem; 1999 Feb; 42(4):593-600. PubMed ID: 10052966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interactions of histamine H1-receptor agonists and antagonists with the human histamine H4-receptor.
    Deml KF; Beermann S; Neumann D; Strasser A; Seifert R
    Mol Pharmacol; 2009 Nov; 76(5):1019-30. PubMed ID: 19720730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of 4-(1H-imidazol-4(5)-ylmethyl)pyridine (immethridine) as a novel, potent, and highly selective histamine H(3) receptor agonist.
    Kitbunnadaj R; Zuiderveld OP; Christophe B; Hulscher S; Menge WM; Gelens E; Snip E; Bakker RA; Celanire S; Gillard M; Talaga P; Timmerman H; Leurs R
    J Med Chem; 2004 May; 47(10):2414-7. PubMed ID: 15115383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
    Watanabe M; Kazuta Y; Hayashi H; Yamada S; Matsuda A; Shuto S
    J Med Chem; 2006 Sep; 49(18):5587-96. PubMed ID: 16942032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists.
    Nagase T; Mizutani T; Ishikawa S; Sekino E; Sasaki T; Fujimura T; Ito S; Mitobe Y; Miyamoto Y; Yoshimoto R; Tanaka T; Ishihara A; Takenaga N; Tokita S; Fukami T; Sato N
    J Med Chem; 2008 Aug; 51(15):4780-9. PubMed ID: 18598020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. S-[2-(4-imidazolyl)ethyl]isothiourea, a highly specific and potent histamine H3 receptor agonist.
    Garbarg M; Arrang JM; Rouleau A; Ligneau X; Tuong MD; Schwartz JC; Ganellin CR
    J Pharmacol Exp Ther; 1992 Oct; 263(1):304-10. PubMed ID: 1383495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Involvement of histamine receptors in SAPK/JNK phosphorylation.
    Dandekar RD; Khan MM
    Int Immunopharmacol; 2012 Jun; 13(2):190-6. PubMed ID: 22487127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Search for novel leads for histamine H3-receptor antagonists: oxygen-containing derivatives.
    Stark H; Hüls A; Ligneau X; Arrang JM; Schwartz JC; Schunack W
    Pharmazie; 1997 Jul; 52(7):495-500. PubMed ID: 9266588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and structure-activity relationships of cyanoguanidine-type and structurally related histamine H4 receptor agonists.
    Igel P; Geyer R; Strasser A; Dove S; Seifert R; Buschauer A
    J Med Chem; 2009 Oct; 52(20):6297-313. PubMed ID: 19791743
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ergoline-derived inverse agonists of the human h3 receptor for the treatment of narcolepsy.
    Auberson YP; Troxler T; Zhang X; Yang CR; Fendt M; Feuerbach D; Liu YC; Lagu B; Lerchner A; Perrone M; Lei L; Zhang C; Wang C; Wang TL; Bock MG
    ChemMedChem; 2014 Aug; 9(8):1683-96. PubMed ID: 24850792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist.
    Ligneau X; Lin J; Vanni-Mercier G; Jouvet M; Muir JL; Ganellin CR; Stark H; Elz S; Schunack W; Schwartz J
    J Pharmacol Exp Ther; 1998 Nov; 287(2):658-66. PubMed ID: 9808693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects.
    Esbenshade TA; Krueger KM; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Fox GB; Faghih R; Bennani YL; Williams M; Hancock AA
    J Pharmacol Exp Ther; 2003 Jun; 305(3):887-96. PubMed ID: 12606603
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.
    Govoni M; Bakker RA; van de Wetering I; Smit MJ; Menge WM; Timmerman H; Elz S; Schunack W; Leurs R
    J Med Chem; 2003 Dec; 46(26):5812-24. PubMed ID: 14667234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. N-substituted piperidinyl alkyl imidazoles: discovery of methimepip as a potent and selective histamine H3 receptor agonist.
    Kitbunnadaj R; Hashimoto T; Poli E; Zuiderveld OP; Menozzi A; Hidaka R; de Esch IJ; Bakker RA; Menge WM; Yamatodani A; Coruzzi G; Timmerman H; Leurs R
    J Med Chem; 2005 Mar; 48(6):2100-7. PubMed ID: 15771452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel nonimidazole histamine H3 receptor antagonists: 1-(4-(phenoxymethyl)benzyl)piperidines and related compounds.
    Mikó T; Ligneau X; Pertz HH; Ganellin CR; Arrang JM; Schwartz JC; Schunack W; Stark H
    J Med Chem; 2003 Apr; 46(8):1523-30. PubMed ID: 12672253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unexpected partial H1-receptor agonism of imidazole-type histamine H3-receptor antagonists lacking a basic side chain.
    Sadek B; Elz S; Pertz HH; Stark H; Schunack W
    Inflamm Res; 2004 Aug; 53 Suppl 2():S109-15. PubMed ID: 15338060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 4-(omega-(alkyloxy)alkyl)-1H-imidazole derivatives as histamine H(3) receptor antagonists/agonists.
    Meier G; Krause M; Hüls A; Ligneau X; Pertz HH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H
    J Med Chem; 2004 May; 47(10):2678-87. PubMed ID: 15115409
    [TBL] [Abstract][Full Text] [Related]  

  • 38. G protein-dependent pharmacology of histamine H3 receptor ligands: evidence for heterogeneous active state receptor conformations.
    Krueger KM; Witte DG; Ireland-Denny L; Miller TR; Baranowski JL; Buckner S; Milicic I; Esbenshade TA; Hancock AA
    J Pharmacol Exp Ther; 2005 Jul; 314(1):271-81. PubMed ID: 15821027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. H3-receptor antagonists: synthesis and structure-activity relationships of para- and meta-substituted 4(5)-phenyl-2-[[2-[4(5)-imidazolyl]ethyl]thio]imidazoles.
    Mor M; Bordi F; Silva C; Rivara S; Crivori P; Plazzi PV; Ballabeni V; Caretta A; Barocelli E; Impicciatore M; Carrupt PA; Testa B
    J Med Chem; 1997 Aug; 40(16):2571-8. PubMed ID: 9258364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy.
    Hancock AA; Diehl MS; Fey TA; Bush EN; Faghih R; Miller TR; Krueger KM; Pratt JK; Cowart MD; Dickinson RW; Shapiro R; Knourek-Segel VE; Droz BA; McDowell CA; Krishna G; Brune ME; Esbenshade TA; Jacobson PB
    Inflamm Res; 2005 Apr; 54 Suppl 1():S27-9. PubMed ID: 15928821
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.